

Subject Index

A

- ACA. *See* Anticentromere antibodies
- Acantholysis, in animals, 515
- Acid pump inhibitors, in systemic sclerosis, 262
- Acitretin, 579
- Acne, in animals, retinoids for, 580
- Acral sclerosis, 234
- Acrodermatitis chronica atrophicans (ACA), 237, 439-440
- Acrodermatitis enteropathica, 576
- Acroscleroderma, 225
- Acrosclerosis, 225-226
- Adenitis, sebaceous, in animals, retinoids for, 581
- Adenocarcinoma, at ostomy sites, 86
- Adhesion molecule
expression
in scleroderma, 370
in systemic sclerosis, 361-363
induction of, by cytokines, 363
in skin of systemic sclerosis patients, 349-350
- Adjuvant therapy
for keloids, 32
for venous leg ulcers, 21
- Adnexal structures, radiation effects on, 61, 63
- Adverse reaction, to food, versus food allergy, 561-562
- Aeroallergen contact, in atopic dermatitis, 566
- Age, influence on systemic sclerosis occurrence, 209-210
- Air plethysmography (APG), in venous leg ulcer evaluation, 15-16
- Alginates, occlusive dressings of, 123
- Allergens, aqueous, 568
- Allergic dermatitis. *See also* Atopic dermatitis
stomal-related, 84
- Allergy
food. *See* Food allergy
red foot from, 575
- Allergy testing
skin, 563
in vitro, in atopic dermatitis, 567-568
- Allografts
cultured, keratinocyte, 174-175
epithelial, 185-186
- Alopecia, 530
in dogs
color dilution, 582
flank, 582
pedal, 575
radiation-induced, 63
- α -adrenoreceptors, in Raynaud's phenomenon, 284
- Alveolitis, in scleroderma, 245
- Amino acids, 343
effect on wound healing, 134-135
- Amlodipine, for Raynaud's phenomenon, 318
- Amphoterecin B, in veterinary dermatology, 540
- ANA. *See* Antinuclear antibodies
- Anal sac glands, canine and feline, 495
- Anemia
hyperbaric oxygen therapy for, 146
in scleroderma renal crisis, 255
- Anesthesia, during veterinary CO2 laser surgery, 587, 589
- Anesthetics, topical, 102, 103t
- Angina, in systemic sclerosis, 267
- Angioedema, in food allergy, 562
- Angiogenesis, 63
- Angiotensin-converting enzyme (ACE), in systemic sclerosis, 291-292
- Angiotensin-converting enzyme (ACE) inhibitors, for systemic sclerosis, 212
for renal crisis in, 255, 256, 257
- Animal models, of systemic sclerosis
of immunogenetics, 353-354
mononuclear cells in skin of, 350
of pathogenesis, 194, 333
- Ankle-brachial index (ABI), in
assessment of arterial leg ulcers, 15
- Anoplura, 546-547
- Antibiotics
for burn wounds, 51-52
for diabetic foot ulcers, 44
systemic, for venous leg ulcers, 22
topical, effect on wound healing, 95-96, 97t-101t
- Antibodies. *See also* specific antibody
scleroderma-specific, 210
in systemic sclerosis, 220
- Anticentromere antibodies (ACA), 286
expression, 342
in silica-induced environemtnal scleroderma, 470
in systemic sclerosis, 218, 221, 338, 339
in renal crisis associated with, 253
- Antifungal therapy, 538, 539-541. *See also* specific agent
- Antigen-antibody reactions, in food allergy, 562
- Antigen-presenting cell, endothelial cell as, 364
- Antihistamines
for atopic dermatitis in dogs, 569
for food allergy, 563
in systemic sclerosis, 262
- Anti-inflammatory agents. *See also* Nonsteroidal anti-inflammatory agents
topical, effect on wound healing, 97, 102t
- Antilymphocytic treatment, for systemic sclerosis, 325
- Antimalarial drugs, 462
for localized scleroderma, 241
- Antimicrobial therapy
for burn wounds, 49-40
in systemic sclerosis, 263
- Antinuclear antibodies (ANA)
in Raynaud's phenomenon, 287
in silica-induced environemtnal scleroderma, 470
in systemic sclerosis, 221, 351
- Antipolymerase III antibodies, in renal involvement in systemic sclerosis, 254
- Antipruritic agents, 569
- Antireflux measures, in systemic sclerosis, 262

- Anti-RNP antibody, in mixed connective tissue disease, 309, 310, 311, 312
 Anti-SCL-70 antibodies, 221, 227, 287
 Anti-UI RNP antibody, 226
 Apocrine tumors, in veterinary dermatology, differentiated from cutaneous melanoma, 512
 Apoptosis, 526
 lymphocyte-associated, 526, 527
 Arginine, role in wound healing, 135-136
 Arrector pili muscles, canine and feline, 496
 Arrhythmias, cardiac, in systemic sclerosis, 269-271
 Arterial insufficiency ulcers, hyperbaric oxygen therapy for, 148
 Arterial ulcers, 7
 leg, 14
 assessment of, 15
 diagnosis of, 133
 symptoms of, 11
 Arteriography, in Raynaud's phenomenon, 284
 Arterioles, coronary, in systemic sclerosis, 268, 269
 Arteriovenous anastomoses, 496
 Arthralgias, in systemic sclerosis, 277
 Arthritis, in systemic sclerosis, 277, 278, 279, 280
 Artichial glands, canine and feline, 495
 Artificial skin
 biological skin substitutes with cultured cells, 185-188
 for burn wounds, 53
 permanent biosynthetic dermis, 185
 properties of, 183-184
 temporary synthetic and biosynthetic, 184-185
 Aspirin, for systemic sclerosis, 326, 327
 Ataxia telangiectasia (AT), 344
 Atopic dermatitis, in dogs, 565
 clinical findings in, 566
 diagnosis of, 567-568
 pathogenesis of, 565-566
 treatment of, 568-569
 Atrophoderma Pasini-Pierini, 437
 Autoantibodies, in systemic sclerosis, 338-339, 351
 classification according to, 207-208
 production of, immunogenetics of, 352
 Autoantigens, in systemic sclerosis, 351-352
 Autografts
 cultured, keratinocyte, 171-172
 epithelial, 185-186
 Autoimmune skin disease, in veterinary dermatology, 515
 Avian scleroderma, 426-427
 Axial flaps, for decubitus ulcers, 76, 78
 Azathioprine, 451, 462
- B**
 B-cell epitopes of systemic sclerosis-specific autoantibodies, 351-352
 Bacillus amyloliquefaciens, 459
 Bacitracin, 97
 Barotrauma, from hyperbaric oxygen therapy, 143
 Basal cell, radiation effects on, 60, 61
 Basal cell carcinoma
 at ostomy sites, 86
 in veterinary dermatology, differentiated from cutaneous melanoma, 511-512
 Basal cell tumor, in veterinary dermatology, differentiated from cutaneous melanoma, 511-512
 Basement membrane zone, canine and feline skin, 493
 Behavioral therapy, for Raynaud's phenomenon, 318
 Benzoyl peroxide, for seborrheic skin disorders in dogs, 556
 Beta-thromboglobulin, 294
 Bilaminate membrane, 184
 Biobrane, 125, 184
 Biologic dressings, for burn wounds, 50
 Biologic skin substitutes, with cultured cells, 185-188
 Biosynthetic skin
 permanent, 185
 temporary, 184-185
 Blacks. *See also* Race
 systemic sclerosis in, 209, 210
 Blastomyces, 540
 dermatitis, 539
 Blastomycosis, in veterinary dermatology, 539
 Bleomycin, 340
 -induced fibrosis, animal models of, 425-426
 systemic sclerosis development and, 344
 Blood pressure, systolic, in Raynaud's phenomenon, 287
 Bone, involvement in systemic sclerosis, 280
 Bone marrow transplantation, scleroderma-dermatomyositis following, 299
 Borrelia burgdorferi
 antibodies to, 299, 475-476
 linear scleroderma and morphea from, 237
 localized scleroderma related to, 194, 333, 475-478
 Bowel herniation, 88
 Boyle's law, 142
 Bromelain, effect on wound healing, 103, 108
 Bronchiolitis, in scleroderma, 249
 Bronchoalveolar lavage
 fluid, mononuclear cells in, 350
 in scleroderma, 243-244, 245-246
 Buerger's disease. *See* Thromboangiitis obliterans
 Bupivacaine, topical, 102
 Burn wounds, 47, 53
 advances in care, 52
 artificial skin for. *See* Artificial skin
 clinical management of, 50-51
 concentric zones, 47
 depth of injury, 47
 estimation of, 48
 diagnosis of, 47-48
 full-thickness, 47-48, 53
 clinical management of, 51
 hyperbaric oxygen therapy for, 146-147
 infectious complications of, 52-53
 partial thickness, 47, 48, 53
 partial-thickness
 clinical management of, 50-51
 superficial, 47
 pathophysiology of, 47
 principles of care, 48-50
 'rule of nines,' 48
 surgical management of, 51-52
- C**
 c-fos oncogene, 421
 c-myc oncogene, in pathogenesis of systemic sclerosis, 419, 421
 c-myc oncogene, 421
 c-sis oncogene, 420
 C4 typing, in systemic sclerosis, 340, 341
 Cadexomer iodine, for venous leg ulcers, 22-23, 24
 Calcification, in systemic sclerosis, 278
 Calcinosis. *See also* CREST syndrome
 subcutaneous, 211
 in systemic sclerosis, 231, 232, 278
 Calcium channel blockers. *See also* specific agent
 for Raynaud's phenomenon, 318-319, 320
 for systemic sclerosis, 213, 271-272, 326
 Calcium deposits, subcutaneous, in systemic sclerosis, 327
 Calluses, foot, comparative dermatology, 574
 Capillaries, in Raynaud's phenomenon, 286
 Capillaroscopic abnormalities, in silica-induced environmental scleroderma, 469
 Captopril, 306
 for systemic sclerosis, 272, 326
 Carbidopa, 454
 Carbohydrate, effect on wound healing, 134
 Carboprostacyclin, for systemic sclerosis, 326
 Cardiopulmonary workup, in systemic sclerosis, 273

- Carmustine, for cutaneous lymphoma, 503
- Casein hydrolysis, 103
- Casts, for diabetic foot ulcers, 41-44
- Cats
- acne in, retinoids for, 580
 - cutaneous lymphoma in. *See* Lymphoma, cutaneous, in companion animals
 - fleas in, 543. *See also* Fleas
 - food allergy in. *See* Food allergy, in veterinary dermatology
 - foot and nail diseases in. *See* Foot and nail diseases, in humans, cats, and dogs
 - normal skin, histologic features of, 491-496
 - pigmented lesions of the skin, 507-514. *See also* Pigmented lesions
- CCAAT-binding factor, 389
- CD3+ cells, 349
- CD4 cells, 343, 363, 501
- in peripheral blood of systemic sclerosis patients, 349
 - in systemic sclerosis, 294
- CD8 cells, 294, 343, 363, 501
- CD29 cells, 343, 349
- CD45 RA cells, 343
- Cell
- cultured, biological skin substitute with, 185-188
 - of immune system, in systemic sclerosis, numbers and activation state of, 349-350
- Cell cycle, radiation sensitivity and, 59
- Cell killing, radiation-related, 59
- Cellular immunity, in systemic sclerosis, 351
- in tight skin mouse model, 429-430
- Cellularity, of keloids, 28
- Central nervous system, oxygen toxicity, 143
- Ceruminous glands, canine and feline, 495
- Ceruminous tumors, in veterinary dermatology, differentiated from cutaneous melanoma, 512
- Charcot foot, 39
- Chemical agents, systemic sclerosis development related to, 211
- Chemotaxis, 157
- Cheyletiella, 546
- blakei, 545
 - parasitavorax, 545
 - yasguri, 545
- Cheyletiellosis, comparative dermatology, 545-546
- Children
- congenital fascial dystrophy in, 234
 - disabling pansclerotic morphea of, 239
 - eosinophilic fasciitis in, 450
 - premature aging in, 444. *See also* Progeria
- Chondroderma in, 194, 299, 334
- management of, 305-306
 - subsets of, 300-302
 - systemic sclerosis, 302-305
- Chloroquine, 451
- Chondroitin 4-sulfate, in keloids and hypertrophic scars, 29
- Chondrolysis, 279
- Chromosomal breakage rate, increased, 343
- Chromosomes
- breakage, in systemic sclerosis, 210
 - damage to, in systemic sclerosis, 343-344
 - double minute, 344
 - involved in scleroderma, 339-340
- Chymase, 350
- mediation of mast cell by, 401
- Cimetidine, 451
- Circumanal gland, 494
- Cisapride, in systemic sclerosis, 262
- Clear cells, 492
- Clostridial gas gangrene, hyperbaric oxygen therapy for, 145
- Clostridium perfringens, 145
- Clotrimazole, 532
- CO2 laser surgery, in veterinary dermatology, 587-589
- Coccidioides, 540
- Cognitive difficulties, in eosinophilia-myalgia syndrome, 462
- Colchicine
- for keloids, 32
 - for systemic sclerosis, 326
- Cold exposure, Raynaud's phenomenon and. *See* Raynaud's phenomenon
- Cold exposure, Raynaud's phenomenon and, 283
- Collagen
- in keloids and hypertrophic scars, 29
 - metabolism
 - in silica-induced environmental scleroderma, 470-471
 - in normal skin, 387-391
 - radiation effects on, 61
 - synthesis, 135-136
 - in systemic sclerosis
 - excessive accumulation of, 391
 - type V, 389, 391
 - type IV, 389
 - type I, 387-388, 391
 - type VII, 389-390, 391
 - type VI, 389, 391
 - type III, 389, 391
 - type II, 388
 - N-terminal propeptide of (PIINP), 292
- Collagen fibers, 89
- Collagen gels, 411
- Collagen gene expression, in localized scleroderma, 238
- Collagen-glycosaminoglycan (GAG) matrix, for skin substitute, 187, 188
- Collagenase, topical, effect on wound healing, 103
- Collodion occlusive dressings, 125
- Colloid bodies, 526
- Colon, involvement in systemic sclerosis, 261, 262
- Colonization, 125-126
- Colostomies, 81. *See also* Stomal wounds
- Comedo syndrome, schnauzer, 581
- Comparative dermatology. *See also* Veterinary dermatology
- commentary on, 481
 - comparative pathology of pemphigus in dogs and humans, 515-524
 - current status, 488
 - cutaneous drug eruptions with epidermal necrosis, 525-528
 - diseases of the foot and nails, in humans, cats, and dogs, 573-577
 - historical overview, 487-488
 - parasitic disorders, 543-548
- Comparative Dermatology Study Group, 488-489
- Compartment syndromes, hyperbaric oxygen therapy for, 146
- Compression, external, for venous leg ulcers, 20, 21
- Compression bandage, 130
- for venous leg ulcers, 22
- Compression stockings, for venous leg ulcers, 20
- Conduction tract abnormalities, in systemic sclerosis, 269-270
- Congenital fascial dystrophy (stiff skin syndrome), 444-445
- Connective tissue
- alterations, in systemic sclerosis, 387-394
 - disorders of, 194
 - keloids related to, 28
 - metabolism, abnormalities, in tight skin mouse, 430-431
 - turnover, role of metalloproteinases in regulation of, 381-382
- Coronary circulation, in systemic sclerosis, 268-269
- Corticosteroids, 130. *See also* Glucocorticoids; specific agent
- for food allergy, 563
 - for juvenile scleroderma, 306
 - for keloids and hypertrophic scars, 30
 - for scleroderma renal crisis, 255
 - for stomal wounds, 83
 - for systemic sclerosis, 213, 324
- Cough, in eosinophilia-myalgia syndrome, 461
- CREST (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, telangiectasia) syndrome, 219,

- 227, 288
 diagnosis of, 286
 features of, 225
 juvenile, 302
 in renal crisis associated with systemic sclerosis, 253
 skin changes in, 230
 Crow-Fukase syndrome, 234
 Crush injuries, hyperbaric oxygen therapy for, 146
 Cryotherapy, for keloids and hypertrophic scars, 31
 Cryptococcosis, in veterinary dermatology, 538-539
 Cryptococcus, 540
 neoformans, 538
 Ctenocephalides felis, 543
 Cutaneous lymphocyte antigen (CLT), 503
 Cutaneous lymphoma. *See* Lymphoma, cutaneous
 Cutaneous melanoma (melanocytoma), in veterinary dermatology, 507
 benign differentiated from malignant melanoma, 508
 differential diagnosis of, 511-513
 histopathology of, 508-511
 incidence of, 507-508
 patterns of, 510
 Cyanoacrylates, 108
 Cyclofenil, for systemic sclerosis, 326
 Cyclophosphamide, 462
 Cyclosporin, for systemic sclerosis, 325
 Cyclosporin A, 451, 462
 Cyst, in veterinary dermatology, differentiated from cutaneous melanoma, 513
 Cytokine(s)
 effects on wound healing in radiation damaged skin, 66
 impact on lymphocyte-endothelial cell interaction, 363-364
 in scleroderma, 333
 in systemic sclerosis, 349, 352-353, 407-412
 IL-2, 408
 IL-4, 409
 IL-6, 409-410
 levels, 352-353
 PDGF, 411-412
 pulmonary, 412
 role in pathogenesis of, 193-194
 TGF- β , 410-411
 Cytokine growth factor, in venous leg ulcers, 23
 Cytotoxic agents, for juvenile scleroderma, 306
- D**
 Dandruff, 545, 546
 Debridement, 129
 for burn wounds, 48
 for diabetic foot ulcers, 40, 41
 for venous leg ulcers, 20-21
 Decompression sickness, from hyperbaric oxygen therapy, 143
 Decubitus ulcers, 71, 129
 defined, 71
 dos and don'ts in, 130
 epidemiology of, 71-72
 leg, 14
 pathophysiology and risk factors, 72-73
 prevention of, 73-74
 staging system for, 72
 treatment of, 74-78
 Demodex, 547, 548
 canis, 547
 Demodicosis, comparative dermatology, 547-548
 Dendritic cells, canine and feline skin, 492-493
 Dermal-epidermal grafts, composite, 177, 186-188
 Dermal remodeling, 63
 Dermatitis, 130
 atopic, 565-571. *See also* Atopic dermatitis
 necrolytic, superficial, 576
 seborrheic, 580-581. *See also* Seborrheic skin disorders
 Dermatomyositis, 299
 Dermatophytosis, in veterinary dermatology, 529-533
 Dermatoses, of dogs, 552
 lichenoid-psoriasiform, 552
 Dermis
 canine and feline, 495-496
 in localized scleroderma, 237
 in systemic sclerosis, 233
 Dermoepidermal junction, in canine and feline skin, 493
 Desmoglein, 516
 Desquamation, 60
 Dessication, wound, prevention of, 124
 Dextranomer, 129
 Diabetes
 foot wounds in, 39-44
 hyperbaric oxygen therapy for, 147-148
 leg ulcers related to, 13-14
 wound healing in, 134
 Dialysis, in scleroderma renal crisis, 256, 257
 Dietary supplements, in systemic sclerosis, 263
 Digit. *See also* Fingers; Toes
 ischemically compromised, in Raynaud's phenomenon, treatment of, 320
 ulcers, 326
 Diltiazem, for Raynaud's phenomenon, 318
 Diphenylhydantoin, 241
 Dipyrindamole, for systemic sclerosis, 272, 326, 327
 Disease activity, in systemic sclerosis, markers of, 291-294
 Disease-modifying therapies, for systemic sclerosis, 324-327
 Diving physics and physiology, related to hyperbaric oxygen therapy, 142
 DNA, level, in scleroderma, 341
 Dogs
 acne in, retinoids for, 580
 atopic dermatitis in. *See* Atopic dermatitis, in dogs
 cutaneous lymphoma in. *See* Lymphoma, cutaneous, in companion animals
 fleas in, 543. *See also* Fleas
 food allergy in. *See* Food allergy, in veterinary dermatology
 foot and nail diseases in. *See* Foot and nail diseases, in humans, cats, and dogs
 ichthyosis in, 581
 keratinization disorders in, 580
 normal skin, histologic features of, 491-496
 pemphigus in. *See* Pemphigus, in dogs and humans
 pigmented lesions of the skin, 507-514. *See also* Pigmented lesions, in animals
 scabies in, 545
 seborrheic skin disorders in. *See* Seborrheic skin disorders, in dogs
 skin, compared with human skin, 515-516
 DR3, 342
 Dressings
 for keloids and hypertrophic scars, 33
 occlusive. *See* Occlusive dressings
 for venous leg ulcers, 21
 Drug eruptions, pathologic and comparative aspects, 525
 erythema multiforme, 526-527
 fixed drug eruptions, 525-526
 toxic epidermal necrolysis, 527-528
 Drug therapy. *See also* specific agent for juvenile scleroderma, 306
 Duodenum, involvement in systemic sclerosis, 259
 Duoderm, 184
 Duplex scanning, in arterial leg ulcer assessment, 15
 Dyspnea
 in eosinophilia-myalgia syndrome, 461
 in eosinophilic fasciitis, 450
 in systemic sclerosis, 211, 267
- E**
 Ear(s), in food allergy, 562
 Earlobe keloids, 28
 treatment of, 31

- Eccrine glands, canine and feline, 495
Ectoparasites, 543
Ectopy, in systemic sclerosis, 270
Edema, in leg ulcers, 12
Elastic bandage, 130
Elastic fibers, 89
 in normal skin, 390, 391
 in scleroderma skin, 392
Elastin, 390
Elastogenic chemical agents, systemic sclerosis development and, 344
Elderly, decubitus ulcers in, 71, 72, 73
Electrical stimulation
 effects on wound healing, 124
 in radiation damaged skin, 66
 for venous leg ulcers, 21-22
Endomyocardial involvement in systemic sclerosis, 270
Endopeptidase, neutral, in systemic sclerosis, 292
Endothelial cell
 function, cytokine modulation of, 364
 as immune costimulator, 364-365
 as target of immune activity, 365
Endothelial involvement, in systemic sclerosis, 333
 markers of, 291-296
Endothelin, levels, in systemic sclerosis, 292
Endothelin-1 (ET-1)
 levels, in Raynaud's phenomenon, 285-286
 for systemic sclerosis, 328
Endothelium, vascular, lymphocyte interactions with, in systemic sclerosis, 361-366
Energy requirements, for wound healing, 134
Enilconazole, 532
Environmental influences, related to systemic sclerosis, 211
Environmental scleroderma, 194, 234, 334, 467, 471-472
 genetic factors in, 467
 pathogenesis of, 467-469
 silica-related, 469-471
Enzymes
 exogenous, effect on wound healing, 102
 mediation of mast cell by, 400
Eosinophilia, 460
Eosinophilia-myalgia syndrome (EMS), 211, 334, 457, 462
 clinical features of, 460-461
 differential diagnosis of, 233-234
 eosinophilic fasciitis and, 452-454
 epidemiology of, 458-460
 etiology of, 452-453
 histopathology of, 461-462
 treatment and course of, 462
 L-tryptophan metabolism and, 457-458
Eosinophilic fasciitis, 233, 449
 in children, 450
 clinical features of, 449
 etiology/pathogenesis of, 452
 extracutaneous manifestations, 449-450
 histopathology of, 450-451
 laboratory findings in, 450
 treatment of, 451-452
Eosinophilic nucleoli, in cutaneous malignant melanoma, in animals, 510
Epidermal cells, radiation effects on, 60
Epidermal growth factor (EGF), effect on wound healing, 109, 115, 158, 162, 163
Epidermis
 canine and feline, 491-493, 515-516
 reestablishment of, in wound healing, 63
Epidermolysis bullosa, dystrophic, 125
Epithelial allografts, cultured, 186
Epithelial autografts, cultured, 185-186
Epithelial neoplasms, 507
Epithelialization of wounds
 occlusion effects on, 124
 rate of, 121
Epithelioid cells, in cutaneous melanoma in animals, 510
Epithelium, cultured, 171
Epitrichial glands, canine and feline, 495
Erosion, defined, 3
Erythema multiforme (EM), pathologic and comparative aspects, 525, 526-527
Erythromycin, 263
Eschar, 52
Escharotomy, 48
Esophageal stricture, 211
Esophageal dysfunction. *See* CREST syndrome
Esophagus, involvement in systemic sclerosis, 260-261, 262, 328
Ethylene, chlorinated, environmental scleroderma induced by, 467-469
Etretnate, in veterinary dermatology, 579, 581
 effect on squamous cell carcinoma, 584
 for keratinization disorders, 580-581
 for seborrheic skin disorders in dogs, 557
Exfoliative disease, comparative dermatology, 575-576
Extracellular matrix, 63
 biosynthesis of, 372
 collagen of, 387
 components of, 407-408
 altered adhesion of scleroderma fibroblasts to, 380-381
 altered production of, by scleroderma fibroblasts, 381
 in pathogenesis of systemic sclerosis, 419-422
 proteins of, fibroblast chemotactic activity and, 380

F
Face, involvement in systemic sclerosis, 230-231, 323
Facial hemiatrophy, progressive, 437
Factor XIII, for systemic sclerosis, 326
Factor XIIIa, in eosinophilia-myalgia syndrome, 461
Familial factors, related to systemic sclerosis occurrence, 210-211
Fascial dystrophy, congenital, 234, 444-445, 449-454
Fasciitis, eosinophilic, 233, 449-454. *See also* Eosinophilic fasciitis
Fasciotomy, 48
Fatigue, in eosinophilia-myalgia syndrome, 462
Fatty acids
 essential, for atopic dermatitis in dogs, 569
 for seborrheic skin disorders in dogs, 557
Fecal incontinence, 72
Fibrillin, 390
Fibrin glue, effect on wound healing, 108, 108t
Fibrinoid necrosis, in scleroderma renal crisis, 255
Fibroblast, 63, 187
 heterogeneity, 374
 proliferation of, 372
 radiation effects on, 61
 in scleroderma
 expression of ICAM-1 on, 370-371, 372
 replication of, 246
 in systemic sclerosis, 379-383
 activation, markers of, 292
 altered adhesion to extracellular matrix components, 380-381
 altered production of extracellular matrix components by, 381
 chemotactic activity, extracellular matrix proteins and, 380
 function, 333, 369-374
 impact of endothelial cell-lymphocyte interaction on, 365-366
 subpopulations of, 379-380
 in three-dimensional culture systems, 382-383
Fibroblast cultures, keloid, 29, 33
Fibroblast growth factor (FGF)
 basic (bFGF)
 effect on wound healing, 115, 163
 gene transcription, 421
 effect on wound healing, 158, 159, 162
Fibronectin, 63
 in normal skin, 390
 in scleroderma skin, 392

- Fibrosarcoma, 574-575
- Fibrosis
- induced by exposure to organic solvents, animal models of, 426
 - induced by injections of glycosaminoglycans from urine of systemic sclerosis patients into mice, 426
 - interstitial, in children, 305
 - pulmonary, 211, 342
 - bleomycin-induced, animal models of, 425-426
 - in scleroderma, 246, 248
 - tissue, impact of endothelial cell-lymphocyte interaction on, 365-366
- Film dressings, polymer, 121, 122
- Fingers
- in Raynaud's phenomenon, 283
 - in systemic sclerosis, 229, 231-232
- Fissure, defined, 3
- Fistulae, esophageal-atrial, in systemic sclerosis, 268
- Flaps, for decubitus ulcers, 76, 78t, 78
- Fleas
- allergy to, 565
 - comparative dermatology, 543-544
- Fluconazole, use in veterinary dermatology, 540-541
- Fluid, wound, 124
- Fluocinolone, for atopic dermatitis in dogs, 569
- 5-Fluorouracil, 129
- Foam dressings, polymer, 122
- Folliculitis, 83
- Malassezia, 534
 - staphylococcal, 532
- Food allergy, in veterinary dermatology, 559, 564
- versus adverse reaction, 561-562
 - clinical signs of, 562-563
 - diagnosis of, 563
 - historical perspective, 559-560
 - incidence of, 560-561
 - pathogenesis of, 562
 - treatment of, 563
- Foot and nail diseases, in humans, cats, and dogs, 573
- calluses, 574
 - exfoliative disease, 575-576
 - onychocryptosis, 573
 - onychogryphosis, 573-574
 - paronychia, 574-575
 - red foot, 575
 - ulcerative disease, 575
- Foot wounds, in diabetics, 39
- evaluation of, 40
 - therapy for, 41-44
 - types of ulcers, 39-40
- Free edge effect, 63
- Free radicals, for venous leg ulcers, 23
- Friction forces, decubitus ulcers related to, 72
- Frontoparietal lesions, 237
- Full-thickness wounds, occlusive dressings for, 123
- Fungal diseases, in veterinary dermatology
- antifungal therapy, 539-541
 - subcutaneous mycoses, 535-538
 - superficial mycoses, 529-535
 - systemic mycoses, 538-539
- Furunculosis, Malassezia, 534
- Fusiform cells, in cutaneous melanoma in animals, 510
- G**
- Gamma rays, 57
- Gas diffusion (DLCO), in scleroderma, 243, 244, 245, 246, 249
- Gas gangrene, clostridial hyperbaric oxygen therapy for, 145
- Gastroesophageal reflux, in systemic sclerosis, 260, 261, 262
- Gastrointestinal involvement
- in eosinophilia-myalgia syndrome, 461
 - in scleroderma, 194, 334
 - in systemic sclerosis, 259-264, 328
- Gender, related to scleroderma development, 209-210, 340
- Generic dog food syndrome, 576
- Genetics
- related to scleroderma, 337-344, 467
 - interlinking of components, 343
 - related to systemic sclerosis occurrence, 210-211, 333
- Glabrous skin, canine and feline, 491-492
- Glomerular changes, in scleroderma renal crisis, 255
- Glomus cells, 496
- Glucocorticoids. *See also* Corticosteroids
- for atopic dermatitis in dogs, 569
 - for localized scleroderma, 241
- Glucose, effect on wound healing, 134
- Glutamine, effect on wound healing, 134-135
- Glycocalyx, food allergy in animals and, 561
- Glycoprotein, desmosomal, 516
- Glycosaminoglycan (GAG), 187, 188
- biosynthesis of, in scleroderma, 392, 393
 - secretion, in morphea, 241
 - in tight skin mouse, 430
 - from urine of systemic sclerosis patients, injection into mice, fibrosis induced by, 426
- Graft
- for burn wounds, 51, 52-53
 - keratinocyte. *See* Keratinocyte grafts
 - use of hyperbaric oxygen therapy in, 148-149
- Graft-versus-host disease (GVHD)
- animal models of, 425
 - chronic, 350, 354
 - sclerodermiform, 440
- Gramicidin, 97
- Granulation tissue, formation of, 63
- Grenz zone, 510
- Griseofulvin
- for systemic sclerosis, 321
 - in veterinary dermatology, 539-540
- Growth factors. *See also* specific growth factor
- in keloids, 29
 - in pathogenesis of systemic sclerosis, 333, 419-422
 - topical, effect on wound healing, 108, 109t-115t
 - in wound healing, 157
 - background, 157-158
 - characteristics of, 158-161
 - human studies on, 163-164
 - as supplements in experimental models, 161-163
- Gut
- food allergy reactions in, 562
 - involvement in systemic sclerosis, 259, 260
- H**
- Hair, canine and feline
- growth of, 493-494
 - specialized, 494
- Hair follicle. *See also* Folliculitis
- canine and feline, 493, 496, 515
 - dermatophytosis of, 529
 - dysplasias, in animals, retinoids for, 581-582
 - growth and senescence, radiation effects on, 63
- Hair shaft, canine and feline, dermatophytosis of, 529
- Haired skin, canine and feline, 491
- Hand, in systemic sclerosis, 230
- Heart
- involvement in eosinophilia-myalgia syndrome, 461
 - involvement in systemic sclerosis, 267-273
 - animal models of, 429
 - in children, 305
- Heat, 130
- Hemangioma, 511
- Hemangiosarcoma, 511
- Hematologic ulcers, leg, 13
- Hematological analysis, in systemic sclerosis, 291
- Hemorrhage, from stoma, 85
- Henry's law, 142
- Hepatoid glands, canine and feline, 494-495
- Histamine. *See also* Antihistamines
- mediation of mast cell by, 399-400
- Histologic findings, in eosinophilic fasciitis, 450

- Histoplasma, 540
History
 for diagnosis and assessment of leg ulcers, 11-12
 in Raynaud's phenomenon diagnosis, 286
HLA associations
 in mixed connective tissue disease, 313-314
 in scleroderma, 341, 342
HLA-II antigen, in localized scleroderma, 238
HLA studies, in systemic sclerosis, 210
HLA typing, 343
Home remedies, 130
Homologous disease, animal models of, 425
Hormones, keloids related to, 28
Horse, pigmented lesions of the skin, 507-514. *See also* Pigmented lesions, in animals
Humoral immunity, in systemic sclerosis, 351-352
 tight skin mouse model of, 429
Hyaluronic acid, 64
Hydrocolloid dressings
 occlusive, 122, 123, 125, 130
 for venous leg ulcers, 21
Hydrogel dressings, 122, 124
Hydron, 184
Hydrophilic starch, for venous leg ulcers, 22
Hydrotherapy, for burn wounds, 48
Hydroxyproline, 133
Hyperbaric oxygen therapy (HBOT), 141
 background of, 141-142
 clinical indications for, 144-150
 contraindications to, 144
 patient selection for, 150-151
 physics and biology of, 142
 risks and complications of, 143-144
Hyperkeratosis
 in dogs, 556-557
 idiopathic, of nose and foot pads, 575-576
Hyperoxia, 142
 side effects, 144
Hyperpigmentation, 86
Hyperproliferative defect, in seborrheic skin disorders, 551
Hypertension
 pulmonary
 in scleroderma, 249-250, 306
 in systemic sclerosis, 328
 scleroderma renal crisis, 253, 254
 treatment of, 256
Hypertrophic scars, 27, 33-34
 clinical manifestations of, 28
 epidemiology of, 27
 etiology of, 27-28
 pathogenesis of, 28-29
 treatment of, 30-33, 34
Hypoalbuminemia, 72
Hyposensitization, for atopic dermatitis in dogs, 568

I
ICAM-1, expression, 503
 on scleroderma fibroblasts, 370-371, 372
Ichthyosis, canine, 581
IgA, food allergy in animals and, 561
IgE, in atopic dermatitis, 565, 566
IgG
 in atopic dermatitis, 565
 production of, 343
IgGd, in atopic dermatitis, 565
Ileostomies, 81, 86. *See also* Stomal wounds
Iloprost, for Raynaud's phenomenon, 320
Immune abnormalities, in systemic sclerosis, 333, 349-354
Immune activity, 183
 target of, endothelial cell as, 365
Immune costimulator. endothelial cell as, 364-365
Immune modifier techniques, for systemic sclerosis, 324-325
Immunogenetic associations, in systemic sclerosis, 344
Immunologic factors, in silica-induced environmental scleroderma, 470
Immunology, in *Borrelia burgdorferi* infection in morphea, 477-478
Immunopathogenesis of systemic sclerosis, model of, 353-354
Immunoregulatory findings, in mixed connective tissue disease, 313
Immunotherapy, for atopic dermatitis in dogs, 568
Induration
 in eosinophilia-myalgia syndrome, 460
 in leg ulcers, 12
Infants, sclerema neonatorum in, 204
Infection
 surgical, 145-146
 wound, 125-126, 129
 burn wounds, 52-52
Inflammatory conditions, L-tryptophan metabolism in, 457
Inflammatory infiltrate, in eosinophilic fasciitis, 450
Inflammatory phase of wound healing, 63
Insensate foot, 40
Insulin-like growth factors (IGFs), effect on wound healing, 160
Interferon- α , 503
Interferon-gamma (IF- γ)
 impaired production of, 363-364
 for keloids and hypertrophic scars, 33
 role in lymphocyte modulation of fibroblast function, 373-374
 in scleroderma, 247
Interleukin-1 (IL-1)
 effect on wound healing, 161
 levels, in systemic sclerosis, 353
 role in lymphocyte modulation of fibroblast function, 373
Interleukin-2 (IL-2)
 effect on wound healing, 161
 production, in mixed connective tissue disease, 313
 receptors for, 349
 in systemic sclerosis, 294, 353, 408
Interleukin-4 (IL-4)
 role in lymphocyte modulation of fibroblast function, 373
 in scleroderma, 247
 in systemic sclerosis, 353, 409
Interleukin-6 (IL-6)
 role in lymphocyte modulation of fibroblast function, 373
 in systemic sclerosis, 353, 409-410
Internal organ, involvement in systemic sclerosis, animal models of, 429
Interstitial lung disease, in scleroderma, 243-244, 244-249
Interstitial tissue, alterations of, 407
Intimal arterial lesion, impact of endothelial cell-lymphocyte interaction on, 366
Ionizing radiation
 defined, 57
 leg ulcers caused by, 14
 types of, 57
Irritants, 129
Ischemia
 posttraumatic, hyperbaric oxygen therapy for, 146
 skin flap, 149
Ischemic ulcers, in diabetics, 39, 40
Isotretinoin, in veterinary dermatology, 579, 581
 effect on squamous cell carcinoma, 584
 for keratinization disorders, 580
Itraconazole, for dermatophytosis, 532-533
Ivermectin, 546

J
Jaw, osteoradionecrosis of, 149-150
Joint
 involvement in systemic sclerosis, 277-281
 manifestations of scleroderma in, in children, 301

K
Karaya, 82
Karyotyping, in scleroderma, 339, 340
Keloids, 27, 33-34
 clinical manifestations of, 28
 epidemiology of, 27
 etiology of, 27-28
 pathogenesis of, 28-29
 treatment of, 30-31, 33-34

- adjuvant therapy, 32-33
 - surgery, 31-32, 33
 - Keratinization disorders, in dogs, 552, 554, 556
 - Keratinocyte, 63
 - apoptosis, 526
 - canine and feline skin, 492
 - killing of, 526
 - radiation effects on, 60-61
 - Keratinocyte grafts, cultured, 171
 - allografts, 174-175
 - autologous (cultured autografts), 171-172
 - composite (dermal-epidermal) grafts, 177
 - histology of sites treated with, 173-174
 - mechanism of action, 175-177
 - Keratosis, seborrheic, canine,
 - differentiated from cutaneous melanoma, 513
 - Ketanserin
 - for systemic sclerosis, 326
 - for venous leg ulcers, 23
 - Ketoconazole
 - for dermatophytosis, 532
 - in veterinary dermatology, 538, 540
 - Ketotifen, 326, 451
 - Kidney, involvement in scleroderma, 194
 - Killer cells. *See* Natural killer cells
 - Kwashiorkor, 133
 - Kynurenine, 454
 - levels, in systemic sclerosis, 457
 - Kynurenine pathway, in eosinophilia-myalgia syndrome, 458
- L**
- Laminin, 188
 - in normal skin, 390
 - PI fragments, in systemic sclerosis, 292
 - Langerhans cells, canine and feline, 493
 - Large intestine, involvement in systemic sclerosis, 261-262, 263, 328
 - Lasers
 - CO₂, in veterinary dermatology, 587-589
 - helium-neon, 22
 - for keloids, 32
 - Leg ulcers, 3
 - chronic, venous. *See* Venous disease, leg ulcers related to
 - diagnosis and assessment of, 11-16
 - dos and don'ts of, 129, 130
 - Leg varicosities, 4
 - Lentigo simplex, in veterinary dermatology, differentiated from cutaneous melanoma, 513
 - Lice, 546-547
 - Lichen sclerosus et atrophicus (LSA), 438-439
 - relationship with morphea, 240
 - Lichenoid-psoriasiform dermatosis, in dogs, 552
 - Lidocaine, topical, 102
 - Linoleic acid, deficits, in seborrheic skin disorders in dogs, 557
 - Lipids
 - effect on wound healing, 134
 - skin surface, in dogs, seborrheic skin disorders and, 551
 - Lipoatrophies, localized, 437-438
 - Liver, involvement in systemic sclerosis, 262
 - Lund-Bowder chart, modified, for estimating body surface area burns, 48, 49f
 - Lung cancer, 59
 - Lyme borreliosis, 475
 - Lymphatics
 - dermal, canine and feline, 496
 - function of, 90
 - structure of, 89-90
 - Lymphedema, wound healing and, 89-93
 - Lymphocytes, in systemic sclerosis, 349
 - activation, markers of, 294
 - interaction with endothelial cells, 333
 - interactions with vascular endothelium, 361-366
 - modulation of fibroblast function by, 369-374
 - in peripheral blood, 349
 - Lymphocytic alveolitis, in scleroderma, 245
 - Lymphoid tissue, skin-associated, 503
 - Lymphoma
 - cutaneous, in companion animals, 499
 - epidemiology of, 499-500
 - epitheliotropic, 499, 500-502
 - nonepitheliotropic, 499, 502
 - pathogenesis of, 502-503
 - treatment of, 503-504
 - histiolytic, 502
 - T-cell, in animals, 499
 - effect of retinoids on, 584-585
 - Lysosome-associated membrane proteins (LAMPs), 408
- M**
- Macrolide drugs, in systemic sclerosis, 263
 - Macrophage, wound, 157
 - Mafenide, for burn wounds, 53
 - Major histocompatibility complex (MHC)
 - antigens, induction of, by cytokines, 363-364
 - autoantibody production, in scleroderma, 342-343
 - in scleroderma, 337-338, 340-343
 - Malabsorption, in systemic sclerosis, 260, 263
 - Malassezia (pityrosporum) dermatitis, in veterinary dermatology, 533-535
 - Malignant melanoma, in animals, 508, 510-511. *See also* Cutaneous melanoma
 - Mallophagia, 546-547
 - Malnutrition
 - decubitus ulcers related to, 73
 - effect on wound healing, 135-136
 - Massage, in wound healing, 91-92
 - Mast cell, 350
 - biology of, 397-398
 - in eosinophilia-myalgia syndrome, 461
 - mediators of, 399-402
 - origin and distribution of, 398-399
 - in scleroderma, 194, 397, 402-403
 - in systemic sclerosis, 333
 - tumors of, 574-575
 - Mast cell growth factor, 399
 - Mattress, for decubitus ulcers, 130
 - Mechanical devices, for venous leg ulcers, 21-22
 - Mechanical stresses, in diabetic foot ulcers, 40
 - Mechlorethamine, for cutaneous lymphoma, 503
 - Medications, leg ulcers caused by, 14
 - Melanin, 511
 - Melanocytes, canine and feline skin, 492
 - Melanocytoma. *See* Cutaneous melanoma
 - Melanoma. *See also* Cutaneous melanoma; Malignant melanoma
 - foot, comparative dermatology, 574
 - Membrane proteins, lysosome-associated (LAMPs), 408
 - Merkel cells, canine and feline, 493
 - Mesenchymal cells, in eosinophilia-myalgia syndrome, 461
 - Mesenchymal neoplasms, 507
 - Metabolic activity, of keloids, 28
 - Metabolic disease, leg ulcers related to, 13-14
 - Metalloproteinases, role in regulation of connective tissue turnover, 381-382
 - Methotrexate, 451, 462
 - in systemic sclerosis, 325
 - Metoclopramide, in systemic sclerosis, 262
 - MHC. *See* Major histocompatibility complex
 - Mice
 - glycosaminoglycans from urine of SSc patients injected into, fibrosis induced by, 426
 - mast cells of, 399
 - tight skin (Tsk), model of scleroderma, 428-433
 - Miconazole, 532
 - Microsporum, 531
 - canis, 529
 - gypseum, 529
 - vanbreuseghemi, 529
 - Microvascular tissue transfer, for decubitus ulcers, 78
 - Minerals, effect on wound healing, 137
 - Mites

- Cheyletiella, 546
scabies, 545
Mitogen-activated protein (MAP), 420
Mitogenesis, 157
Mixed connective tissue disease (MCTD), 309
clinical observations, 309-312
HLA associations in, 313-314
immunoregulatory findings in, 313
serologic features of, 312-313
in systemic sclerosis, 277-278
Moist wound healing, 121, 184
Monilia, 83
Moniliasis, 86
Monoclonal antibodies, anti-T-cell, 503
Monocyte activation, in systemic sclerosis, markers of, 294
Mononuclear cell
in systemic sclerosis, 349
Mononuclear cells
peripheral blood, stimulation of, 408
in systemic sclerosis, 349-350
in bronchoalveolar lavage fluid, 350
in early systemic sclerosis, 361
in skin of animal models, 350
Morphea, 201. *See also* Scleroderma, localized
Borrelia burgdorferi infection and, 475-478
immunology of, 477-478
clinical aspects of, 238-239
differential diagnosis, 233
disabling pansclerotic, of children, 239
frontoparietal, 240
generalized, 239
guttate, 239
historical approach to, 202-203
juvenile, 299, 300-302
linear, 237, 239
in Lyme borreliosis, clinical findings, 477
profunda, 239
relation of atrophoderma Pasini-Pierini to, 437
relationship with lichen sclerosus et atrophicus, 240
mRNA, levels, in systemic sclerosis, 352-353
Mucosal immune system, food allergy in animals and, 561
Multimerin, 294
Mupirocin, 44
Muscles
canine and feline, 496
involvement in systemic sclerosis, 280
Myalgia, 460, 462. *See also* Eosinophilia-myalgia syndrome
myc oncogene, in pathogenesis of systemic sclerosis, 419-420
Mycoses, in veterinary dermatology
antifungal therapy for, 539-540
subcutaneous, 535-538
superficial, 529-535
systemic, 538-539
Mycosis fungoides (MF)
in animals, 499
clinical features of, 500
effect of retinoids on, 585-585
incidence of, 499
pathology of, 500-501
treatment of, 503-504
leg ulcers caused by, 14
Myeloma, scleredema associated with, 442
Myocardial disease, in systemic sclerosis, 267-268
- N**
Nails
diseases of, in humans, cats and dogs. *See* Foot and nail diseases, in humans, cats, and dogs
structure of, comparative dermatology, 575
in systemic sclerosis, 229
tumors, of nail bed, 574
Natural killer (NK) cells
function, in mixed connective tissue disease, 313
in systemic sclerosis patients, 351
Necrolytic dermatitis, superficial, 576
Necrotic tissue, 129
removal of, 102, 103-108
Neomycin, 97
Neomycin sulfate, 97
Neonatal sclerodermiform progeria, 444
Neostigmin, 260
Neurocognitive dysfunction, in eosinophilia-myalgia syndrome, 460
Neurologic evaluation, in diabetic foot ulcers, 40
Neuropathic ulcers, foot, in diabetes, 39, 40t, 41
treatment of, 44
Neurotoxic mediators, in eosinophilia-myalgia syndrome, 460
Neutrophil, in wound healing, 63
Neutrophilic alveolitis, in scleroderma, 245
Nevus, in veterinary dermatology, 507
Nicardipine
for Raynaud's phenomenon, 318
in systemic sclerosis, 271, 272
Nifedipine
for Raynaud's phenomenon, 318, 320
in systemic sclerosis, 271-272
Nonsteroidal anti-inflammatory agents, 462
for systemic sclerosis, 213, 324
Notoedres cati, 544
Nucleolar antibodies, in scleroderma, 339
Nutrients, effect on wound healing, 134-137
- Nutritional status, 130. *See also* Malnutrition
- O**
Occlusion, wound, microbiology of, 125-126
Occlusive dressings, 121
alginate, 123
background of, 121
in decubitus ulcers, 130
hydrocolloid dressings, 122, 123
hydrogel dressings, 122
keratinocyte grafts acting as, 176
mechanisms of action, 123-125
microbiology of wound occlusion, 125-126
polymer films, 121, 122
potential uses for, 125
for venous leg ulcers, 21
Occupational factors, related to systemic sclerosis occurrence, 210-211
Octreotide, 263, 462
Omeprazole, 262
Oncogenes, in pathogenesis of systemic sclerosis, 333, 419-422
Onychocryptosis, comparative dermatology, 573
Onychogryphosis, comparative dermatology, 573-574
Osteomyelitis, chronic refractory, use of hyperbaric oxygen therapy in, j150
Osteoradionecrosis, of jaw, 149-150
Ostler's Leric nail, comparative dermatology, 573-574
Otraconazole, use in veterinary dermatology, 540
Overlap syndromes, 194, 219, 226
description of, 314
systemic sclerosis and, 233
Oxygen
hyperbaric. *See* Hyperbaric oxygen therapy
modification of tissue response to radiation by, 59
Oxygen toxicity, 143-144
- P**
Pachydermatitis, Malassezia, 533
Pacinian corpuscles, 496
Pagetoid reticulosis, in companion animals, 499, 500
clinical features of, 500
Pan-T-cell antigen, 501
Pancreas, involvement in systemic sclerosis, 262
Panepidermal pustular pemphigus, canine (pemphigus vegetans/erythematosus), 518-522
Paraproteinemia, scleredema associated with, 442
Parasitic disorders, comparative

- dermatology, 543
- cheyletiellosis, 545-546
- demodicosis, 547-548
- fleas, 543-544
- pediculosis, 546-547
- scabies, 544-545
- Parry-Romberg syndrome, 437
- Partial-thickness wounds, 121
 - occlusive dressings for, 123
- Pediculosis, comparative dermatology, 546-547
- Pemphigus
 - comparative dermatology of, 575-576
 - comparative pathology of, in dogs and humans, 515-516, 522
 - panepidermal pustular pemphigus (pemphigus vegetans/erythematosus), canine, 515, 518-522
 - pemphigus foliaceus, canine, 515, 517-518, 521
 - pemphigus vegetans, canine, 515
 - Hallopeau type, 519, 521
 - Neumann type, 519, 521
 - pemphigus vulgaris, canine, 516-517, 521
 - unclassified pemphigus, human, 521
- Penicillamine, 241
 - for keloids, 32
 - for systemic sclerosis, 325
- D-Penicillamine, 451, 462
 - for juvenile scleroderma, 306
 - for systemic sclerosis, 213, 326, 328
- Pentoxifylline
 - for keloids, 32
 - for venous leg ulcers, 22
- Periarticular involvement in systemic sclerosis, 277-281
- Pericardial disease, in systemic sclerosis, 267
- Pericardial effusions, in systemic sclerosis, 271
- Peripheral neuropathy, in eosinophilia-myalgia syndrome, 460
- Peroxide, 44
- Petrolatum, 44
- Phenylketonuria, scleroderma-like lesions in, 441
- Photochemotherapy, extracorporeal, for systemic sclerosis, 325
- Photodamage. *See* Solar-induced disease
- Photophoresis, extracorporeal, 503
- Photoplethysmography, in venous leg ulcer evaluation, 15-16
- Physical examination, for leg ulcer assessment, 12
- Physical therapy, in systemic sclerosis, 327
- Phytohemagglutinin (PHA), 408
- Phytonadione (vitamin K) injection, scleroderma-like plaques after, 441
- Pigmentation
 - canine and feline
 - hair, 494
 - skin, 492
 - in localized scleroderma, 240
 - in systemic sclerosis, 232
- Pigmented lesions, in animals, 507
 - clinical features of, 508
 - cutaneous melanoma, differential diagnosis of, 511-513
 - histopathology of, 508-511
 - incidence of, 507-508
 - prognosis and therapy, 511
- Pillow bridging, 73
- Pilomatrixoma, in veterinary dermatology, differentiated from cutaneous melanoma, 513
- Pilosebaceous unit, 493
- Plantar calluses, comparative dermatology, 574
- Plantar pads, 575
- Plaque, scleroderma-like, after phytonadione injection, 441
- Plasma cell pododermatitis, 575
- Plasma exchange (PE), for systemic sclerosis, 325, 329
- Plasmapheresis, 462
- Plasminogen activator, tissue-type, in systemic sclerosis, 292
- Platelet activating factor, mediation of mast cell by, 400
- Platelet activation, in systemic sclerosis, markers of, 294
- Platelet-derived growth factor (PDGF)
 - effect on wound healing, 124, 159-160, 162
 - fibroblast proliferation and, 372
 - in lung involvement in scleroderma, 248
 - receptor for, 420
 - in systemic sclerosis, 411-412
 - oncogene expression and, 420-421
 - topical, effect on wound healing, 115
- Platelet-derived growth factor α (PDGF α)
 - in lung involvement in scleroderma, 246, 247
 - receptor for, 352
- Platelet-derived growth factor B (PDGF B)
 - in lung involvement in scleroderma, 246, 247
 - receptors for, 352
- Platelet-derived growth factor-BB (PDGF-BB), effect on radiation impairment of wound healing, 64
- Platelet-derived wound healing factor (FDWHF), experimental studies on, 162-163
- Platelet factor 4, 294
- Pneumatosis cystoides intestinalis, 263
- Pneumothorax, 144
- Pododermatitis, plasma cell, 575
- Poikiloderma
 - Rothmund-Thompson, 444
 - with scleroderma-like lesions, 444
- Polyarthralgias, in systemic sclerosis, 327
- Polycythemia vera, leg ulcers related to, 13
- Polymer dressings
 - film, 121, 122
 - foam, 122
- Polymorphism
 - restriction fragment length, analysis, in systemic sclerosis, 340, 341
 - in scleroderma, 337-338
- Polymorphonuclear monocytes (PMNs), 157
- Polymyositis, 233
 - occurrence with scleroderma, 314. *See also* Overlap syndromes
- Polymyxin B sulfate, 97
- Porphyria cutanea tarda (PCT), scleroderma-like changes of, 440-441
- Postphlebotic syndrome, 20
- Potassium iodide (SSKI), for sporotrichosis, 536
- Potassium p-aminobenzoate, 241
- Povidone-iodine, 44
- Prednisone, 324
- Pregnancy
 - hyperbaric oxygen therapy and, 144
 - scleroderma renal crisis in, 255
- Pressure, neuropathic foot ulcers from, 39, 40
- Pressure therapy, for keloids, 32
- Progeria, 444
 - scleroderma-like neonatal, 444
- Prokinetic drugs, in systemic sclerosis, 262
- Propyl 4-hydroxylase, in systemic sclerosis, 292
- Propylene glycol, 97
- Prostacyclin, for systemic sclerosis, 327
- Prostaglandin E1 (PGE1)
 - for systemic sclerosis, 326
 - for venous leg ulcers, 22
- Prostaglandin I2, for systemic sclerosis, 327
- Prostanoids, for Raynaud's phenomenon, 319-320
- Protein malnutrition, 133
- Proteoglycans, mediation of mast cell by, 401
- Protooncogenes, involvement in pathogenesis of systemic sclerosis, 419, 420
- Pruritis, 545
 - in atopic dermatitis in dogs, 568-569
 - in food allergy, 562
- Pseudoallergy, 562
- Pseudomonas, 50
- Pulex irritans, 543

- Pulmonary disease
 in scleroderma, 243-250, 244, 334
 in systemic sclerosis, 425-426
 cytokines in, 412
 juvenile, 305
 treatment of, 328
Pulmonary oxygen toxicity, 143-144
Pulse, assessment of, in leg ulcers, 12
 volume recordings, 15
Punch biopsies, occlusive dressings for, 123
PUVA, 503
Pyoderma
 in atopic dermatitis in dogs, 566
 gangrenosum, 576
 of lower extremities, 14
 stoma-related, 86
Pythiosis, in veterinary dermatology, 536-538
Pythium, 536, 537, 538
 insidiosum, 536
 sp., 536
- R**
- Race, influence on systemic sclerosis occurrence, 209-210
Radiation injury, use of hyperbaric oxygen therapy in, 149
Radiation therapy. *See also* Ionizing radiation
 biology of, 59-60
 delivery of, 57
 dose buildup region, 57-58
 effect on stomal site, 85-86
 effect on wound healing
 augmentation of wound healing in radiation-damaged skin, 65-66
 investigation of, using radiation-impaired models, 64-65
 for keloids, 32
 nominal standard dose, 59
 total treatment time, 59-60
 tumorigenesis, 65
Ram's horn nail, comparative dermatology, 573-574
Random flaps, for decubitus ulcers, 76, 78
ras oncogene, in pathogenesis of systemic sclerosis, 420, 421
Rash, in eosinophilia-myalgia syndrome, 460
Raynaud's phenomenon. *See also* CREST syndrome
 arteriography in, 284
 in children, 302, 306
 description of, 283, 286-287, 288
 diagnosis of, 286-287
 in overlap syndromes, 314
 pathology of, 284
 pathophysiology of, 284-286
 prevalence of, 283
 prognosis of, 283-284
 relationship to scleroderma, 287-288
 relationship to systemic sclerosis, 334
 serology of, 221
 in systemic sclerosis, 211, 212, 213, 217, 218, 324
 onset of, 226
 renal, 255
 treatment of, 327
 treatment of, 317
 behavioral therapy, 318
 calcium channel blockers, 318-319
 general measures, 317
 goals of, 317
 for ischemically compromised digit, 320
 miscellaneous, 320
 prostanoids, 319-320
 recommendations for, 321
 serotonin inhibition, 319
 sympathectomy, 320
 sympatholytics, 320
Reconstruction, of decubitus ulcers, 76-78
Red foot, 575
Refractory wounds, chronic, hyperbaric oxygen therapy for, 147
Renal crisis, in systemic sclerosis, 212, 253-257
 treatment of, 328
Restriction fragment length polymorphism (RFLP) analysis, in systemic sclerosis, 340, 341
Reticulosis, Pagetoid, in companion animals, 499, 500
Retinal, 579
Retinoic acid, 579
Retinoids
 for keloids, 33
 in veterinary dermatology, 503, 579, 580, 585
 for acne, 580
 for follicular dysplasias, 581-582
 for keratinization disorders, 580-581
 for neoplastic diseases, 582-585
 for sebaceous adenitis, 581
 for seborrheic skin disorders in dogs, 557
 spectrum of adverse effects, 585
 synthetic, 579
Retinol. *See* Vitamin A
Rheumatic conditions, L-tryptophan metabolism in, 457
Rheumatism, fibroblastic, 441
Rheumatoid arthritis, leg ulcers caused by, 14
Rheumatoid factor, 277
 in mixed connective tissue disease, 313
Ribs, in systemic sclerosis, 280
Ringworm, 532
Rodent. *See also* Mice
 mast cells of, 399
Round cells, in cutaneous melanoma in animals, 510
Rubor, 12
 'Rule of nines', 48
Rutoside, for venous leg ulcers, 22
- S**
- Salicylic acid, for seborrheic skin disorders in dogs, 555
Saline, for diabetic foot ulcers, 44
Sarcoptes scabiei
 var canis, 544
 var hominis, 544-545
Satellitosis, 525
Scabies, comparative dermatology, 544-545
Scars, hypertrophic. *See* Hypertrophic scars
Schnauzer comedo syndrome, 581
Scleredema adultorum, 204
Sclerema neonatorum, 204
Sclerodactyly, 226, 323. *See also* CREST syndrome
Scleroderma. *See also* Morphea; Systemic sclerosis
 in childhood, 299-306, 334
 circumscribed, 203
 classification of, 333
 color atlas of, 197-200f
 commentary on, 193-194, 333-335
 diffuse, 203, 225, 288
 environmental. *See* Environmental scleroderma
 genetics of, 337-344
 historical approach to, 201-205, 333
 linear
 en coup de sabre, 239
 juvenile, 300-301
 localized, 194, 227, 237, 333
 associated lesions, 239-240
 Borrelia burgdorferi and, 475-478
 clinical aspects of, 238-239
 differential diagnosis in, 240-241
 etiopathogenesis of, 237
 incidence of, 238
 laboratory abnormalities in, 240
 pathology of, 237-238
 prognosis of, 240
 scleroderma-like disorders
 simulating, 437-441
 treatment guidelines for, 241
 lung involvement in, 243-250
 mast cells in, 397-403
 proximal, 218
 relationship of Raynaud's phenomenon to, 287-288
Scleroderma of Buschke, 441-442
Scleroderma-polymyositis overlap syndrome, 314. *See also* Overlap syndromes
Scleroderma-like diseases
 simulating localized scleroderma, 437-441
 simulating systemic scleroderma, 441-445

- Scleromyxedema, 442
- Sclerosis, 202
 localized, treatment of, recent developments in, 323-329
 systemic. *See* Systemic sclerosis
- Sebaceous glands, canine and feline, 494-495
- Sebaceous tumors, in veterinary dermatology, differentiated from cutaneous melanoma, 512
- Seborrheic dermatoses, 581
- Seborrheic keratosis, canine, differentiated from cutaneous melanoma, 513
- Seborrheic plaques, 532
- Seborrheic skin disorders, in veterinary dermatology
 in dogs, 551
 clinical presentation of, 552
 diagnosis of, 553-554
 etiologic classification of, 551-552
 pathogenesis of, 551
 seborrhea oleosa, 552, 556
 seborrhea sicca, 552
 treatment of, 554-557
 primary, retinoids for, 580-581
 seborrhea sicca, 545
- Segmental limb pressure, for arterial ulcer assessment, 15
- Selenium sulfide, for seborrheic skin disorders in dogs, 555-556
- Sensitizers, topical, 129
- Serology, in systemic sclerosis, 221
- Serotonin, in Raynaud's phenomenon, 285
 inhibition of, for Raynaud's phenomenon, 319
- Serum factors, chromosomal aberrations and, 343
- Sex. *See* Gender
- Szary syndrome, in companion animals, 499, 500
 clinical features of, 500
- Shampoos, for seborrheic skin disorders in dogs, 556
- Shave biopsies, occlusive dressings for, 123
- Shearing forces, decubitus ulcers related to, 72
- Sickle cell anemia, leg ulcers related to, 13
- Silica, environmental scleroderma induced by, 469-471
- Silicon gel, for keloids and hypertrophic scars, 33
- Silver sulfadiazine, 65
 occlusive dressings, 125
 topical, 97
 for venous leg ulcers, 23
- Sinus hairs, 494
- Sjögren's syndrome, 243, 245
 in scleroderma, 249
 in systemic sclerosis, rheumatoid factor in, 277
- Skin
 artificial. *See* Artificial skin
 changes, in systemic sclerosis, 213
 normal, biochemical composition of, 387-390
 sclerosis, 217
 thickening of
 in scleroderma renal crisis, 257
 in systemic sclerosis, 211, 212
- Skin substitutes. *See* Artificial skin
- Skin tests, allergy, 563
- Small airway disease, in scleroderma, 244, 249
- Small intestine, involvement in systemic sclerosis, 259-260, 261, 263, 328
- Smoking, Raynaud's phenomenon and, 317
- Sodium hydrochlorite, 129
- Soft tissue, involvement in systemic sclerosis, 278, 280
- Solar-induced disease, in animals, effect of retinoids on, 582-585
- Solvents, organic, fibrosis induced by, animal models of, 426
- Somastatin, in systemic sclerosis, 263
- Somatomedins. *See* Insulin-like growth factors
- Spider bites, brown recluse, hyperbaric oxygen therapy for, 147
- Spina bifida in localized scleroderma, 239, 240
- Sporothrix, 540
- Sporotrichosis, 535-536
- Sprague-Dawley rat, 425
- Squamous cell carcinoma
 in animals, effect of retinoids on, 583, 584
 leg ulcers caused by, 14
 at ostomy sites, 86
- Staphylococcus
 epidermidis, 573
 s aureus, 573
- Stiff skin syndrome, 444-445
- Stomach, involvement in systemic sclerosis, 261, 262-263
- Stomal wounds, 81
 appliances for, 81
 complications of, 83-86
 protective measures, 81-83
 treatment of, 87-88
 types of, 81
- Stratum corneum, canine and feline, 491, 492
- Stratum lucidum, canine and feline, 491, 492
- Streptodornase, 103
- Streptokinase, 103
- Stricture, esophageal, 262
- Sulfur, for seborrheic skin disorders in dogs, 555
- Surgery
 for burn wounds, 51-52
 for decubitus ulcers, 74-78
 for keloids and hypertrophic scars, 31-32, 33
 for venous leg ulcers, 20, 23
- Surgical infections, hyperbaric oxygen therapy in, 145-146
- Suttilains, topical, effect on wound healing, 103
- Sweat glands, canine and feline, 495
- Sympathectomy, for Raynaud's phenomenon, 320
- Sympathetic nervous system, in Raynaud's phenomenon, 284
- Sympatholytics, for Raynaud's phenomenon, 320
- Symptomatic therapies, for systemic sclerosis, 327-329
- Synovial biopsies, in systemic sclerosis, 279-280
- Synovial calcifications, in systemic sclerosis, 278
- Synovial fluid, in systemic sclerosis, 280
- Synthetic skin, temporary, 184-185
- Systemic agents, for venous leg ulcers, 22
- Systemic lupus erythematosus (SLE), 310
- Systemic sclerosis, 213-214
 animal models of, 425-424t
 classification of, 207-208, 217-221, 225-227, 323
 clinical manifestations of, 323
 connective tissue alterations in, 387-394
 cytokines in, 407-412
 diffuse, 219, 220, 323, 337
 disease activity in, markers of, 291-294
 epidemiology of, 207-214, 333
 fibroblast in, 379-383
 gastrointestinal involvement in, 259-264
 heart involvement in, 267-273
 immune abnormalities in, 349-354
 incidence and prevalence studies, 208-209
 intermediate, 323
 joint and periarticular involvement in, 277-281
 juvenile, 299, 302-305
 diffuse cutaneous, 302
 limited, 219, 323, 337
 lymphocyte interactions with the vascular endothelium in, 361-366
 lymphocyte modulation of fibroblast function in, 369-374
 morbidity in, 212-213
 mortality rate for, 210
 natural history of, 211
 occurrence of
 familial, genetic, and occupational factors related to, 210-211
 influence of age, sex, and race on, 209-210

- pathogenesis of, oncogenes, growth factors, and matrix in, 419-422
progressive, 201
renal involvement in, 253-257
scleroderma-like disorders simulating, 441-445
skin in, 229
 differential diagnosis, 233-234
 histopathology of, 232-233
 nonsclerotic changes, 231-232
 patterns of cutaneous disease, 229-230
 pigmentary changes, 232
 treatment of, 234
 vascular lesions, 232
subsets, 219-221
survival in, 211-212
treatment of, 212
 recent developments in, 323-329
truncal, 226
- T**
- T-cell, 89
 activation of, 362
 depletion of, 350
 function in systemic sclerosis patients, 351
 homing to skin, 503
 in mixed connective tissue disease, 313
 primitive precursors, 361
 receptor for, in scleroderma, 339, 343
 stimulation of activation, stimulation of by endocrine cells, 364-365
 in systemic sclerosis, 294, 350
 in peripheral blood, 349
T-cell growth factor. *See* Interleukin-2
T-cell lymphoma. *See* Lymphoma
T-cell stimulatory antigens, in systemic sclerosis patients, identification of, 351
- Tactile hairs, 494
Tail gland, 494, 495
Tars, medicinal, for seborrheic skin disorders in dogs, 555
Telangiectasia. *See* CREST syndrome
Teletherapy, 57
Temperature
 skin, in leg ulcers, 12
 wound, 7-8
Tenascin
 in normal skin, 392
 in scleroderma skin, 392
Tendon ruptures, in systemic sclerosis, 280
Tenosynovitis, in systemic sclerosis, 327
Tetracaine-epinephrine-cocaine (TAC), 102
Thalassemia minor, leg ulcers related to, 13
Thrombin, effects on wound healing in radiation damaged skin, 66
Thromboangiitis obliterans (Buerger's disease), 13
Thrombomodulin, in systemic sclerosis, 292
Thrombospondin, 294
Tincture of benzoin, 130
Tissue, skin, radiation effects on, 60
Tissue damage, in systemic sclerosis, 351
Tissue glues, effect on wound healing, 108, 108t
Tissue loss, following burns, 47
Tissue repair, phases of, 157
Toes, in Raynaud's phenomenon, 283
Topical agents
 for atopic dermatitis in dogs, 569
 historical overview, 487
 for localized scleroderma, 241
 sensitizers and irritants, 129
 for systemic sclerosis, 234
 for venous leg ulcers, 22
 in wound healing, 95
 anesthetics, 102, 103t
 anti-inflammatory agents, 97, 102t
 antimicrobial agents and antibiotics, 95-96, 97t-110t
 growth factors and vulnery agents, 108, 110t-115t
 for removing of necrotic tissue, 102, 103-108
 tissue glues, 108, 108t
Topoisomerase 1, 352
Toxic epidermal necrolysis (TEN), pathologic and comparative aspects, 526, 527-528
Toxic oil epidemic syndrome, 299
Trace elements, effect on wound healing, 137
Transcutaneous oxygen measurement
 in arterial leg ulcer assessment, 15
 for hyperbaric oxygen therapy, 150
Transforming growth factor, effect on wound healing, 158
Transforming growth factor α (TGF α), effect on wound healing, 161
Transforming growth factor- β (TGF- β)
 effect on wound healing, 160-161, 162
 in systemic sclerosis, 410-411
 topical, effect on wound healing, 115
Transforming growth factor- β 1, in keloids, 29
Trauma, keloids related to, 27, 31
Treponema pallidum, 476
Tretinoin, 579
 for keloids, 33
Triamcinolone acetonide
 for keloids and hypertrophic scars, 30
 for localized scleroderma, 241
Trichoepithelioma, in veterinary dermatology, differentiated from cutaneous melanoma, 512-513
Trichophyton, 531
 mentagrophytes, 529, 530
 rubrum, 529, 530
 terrestre, 529
Tryptase, 350
 mediation of mast cell by, 400-401
L-Tryptophan
 ingestion, 194, 211. *See also* Eosinophilia-myalgia syndrome
 eosinophilic fasciitis and, 452-454
 metabolism of, 457-458
Tumor. *See also* specific type of tumor
 in animals, effect of retinoids on, 582-585
 chromosomal aberrations in systemic sclerosis and, 344
 leg ulcers caused by, 14
 pigmented. *See* Pigmented lesions
 radiation therapy for, 57, 58
Tumor cells, at ostomy sites, 86
Tumorigenesis, radiotherapy-related, 65
Tyrosine, 343
- U**
- Ulcer, 3
 arterial, 7
 arterial insufficiency, hyperbaric oxygen therapy for, 148
 chronic, 3, 4
 comparative dermatology, 575
 cutaneous, in systemic sclerosis, treatment of, 327
 decubitus. *See* Decubitus ulcers
 defined, 3
 dos and don'ts in, 130
 foot, in diabetes, 39-40
 leg. *See* Leg ulcers
 parastomal, 86
 in systemic sclerosis, 230
 venous stasis, hyperbaric oxygen therapy for, 148
Ultrasound, pulsed, 22
Unhairs skin, canine and feline, 491-492
Unna boot, 21, 130
Urticaria, in food allergy, 562
- V**
- v-myb oncogene, in pathogenesis of systemic sclerosis, 419
Valvular heart disease, in systemic sclerosis, 270-271
Varicosities, 20
 leg, 4
Vascular lesions
 in systemic sclerosis, 232
 in veterinary dermatology, differentiated from cutaneous melanoma, 513
Vasculature, cutaneous
 canine and feline, 495-496
 radiation effects on, 61
Vasculitis, leg ulcers secondary to, 13
Vasoactive drugs, for systemic sclerosis, 326
Vasoconstriction, 142

- Vasospasm, in Raynaud's phenomenon, 285, 286, 287
- Venous disease
- leg ulcers related to, 11
 - assessment of, 15-16
 - diagnosis of, 13
 - etiology of, 20
 - management of, 19-24
 - occlusive dressings for, 121
 - wounds due to, 7, 8
- Venous hypertension, in leg ulcers, 23
- Venous stasis ulcers, hyperbaric oxygen therapy for, 148
- Ventricular abnormalities, in systemic sclerosis, 268, 270, 271-272
- Vesiculopustular disease, in animals, 515
- Veterinary dermatology. *See also* Comparative dermatology
- atopic dermatitis, 565-571
 - CO₂ laser surgery in, 587-589
 - commentary on, 481
 - cutaneous lymphomas in companion animals, 499-504
 - food allergy, 559-564
 - fungal diseases, 529-541
 - histologic features of normal canine and feline skin, 491-496
 - pigmented lesions of the skin, 507-514
 - retinoids in, 579-586
 - seborrheic skin disorders and their treatment in dogs, 551-557
- Vibration syndrome, 234
- Vibrissae, 494
- Vinyl chloride, ingestion of, 234
- Visceral organs, in eosinophilic fasciitis, 449-450
- Vitamin(s), effect on wound healing, 136-137
- Vitamin A (retinol), 579
- deficiency, effect on wound healing, 137
- Vitamin C, 134, 144
- deficiency, effect on wound healing, 136-137
- Vitamin E, 144
- Vitamin K. *See* Phytonadione
- Vulnerary agents, topical, effect on wound healing, 108, 109t-115t
- vWF, in systemic sclerosis, 291, 292
- W**
- Walking dandruff, 545, 546
- Wedge phenomenon, in decubitus ulcers, 72
- Werner's syndrome, 442-444
- Whiskers, 494
- Wound(s). *See also* Burn wounds
- bursting strength, 64
 - causes of, 95-96
 - chronic
 - defined, 3
 - diagnosis and classification of, 3-9
 - etiologic classification of, 6-8
 - evaluation of, 7
 - measurement and documentation of, 4-6
- closed, 183
- Wound cleansing, for venous leg ulcers, 21
- Wound environment, moist, 121
- Wound healing, 3
- artificial skin for, 183-188
 - delayed, 6
 - dos and don'ts of, 129-130
 - effect of therapeutic radiation on, 57-66
 - future directions in, 1
 - growth factors in, 157-164
 - hyperbaric oxygen and, 141-151
 - keratinocyte grafts for, 171-177
 - lymphedema and, 89-93
 - moist, 184
 - normal, 63-65
 - nutrition in, 133-137. *See also* Malnutrition
 - occlusive dressings and, 121-126
 - topical agents and, 95-115
- X**
- X-rays, 57
- for joint and periarticular involvement in systemic sclerosis, 277-279
- Z**
- Zinc, 97
- deficiency of, 551, 576
 - for venous leg ulcers, 20
- Zinc oxide, for venous leg ulcers, 21
- Zinc sulfate, for venous leg ulcers, 22